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The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients
with advanced hormone-refractory prostate cancer. Forty-eight patients received 35mgm
 2 of weekly docetaxel for 3 out of every 4
weeks, 280mg of estramustine twice daily on days 1–3, 8–10, 15–17 and 400mg of celecoxib twice daily until progression or
toxicity. Cycles were repeated every 28 days for at least six cycles. Patients were evaluated for response and toxicity. Patients
received a median of four cycles (range: 1–9). On an intention-to-treat analysis, prostate-specific antigen (PSA) was decreased
greater than 50% in 28 out of 48 patients (overall response rate: 58%, 95% confidence interval (CI): 44–72) and median duration of
PSA response was 8.0 months (95% CI: 6.9–9.0). After a median follow-up of 11.3 months, the median time to progression was 7.1
months and the median overall survival was 19.2 months. The most frequent severe toxicity was asthenia (15% of patients), diarrhoea
and stomatitis (8% of patients, each). Grade 3/4 neutropenia was reported in two patients. There was a toxic death during the study
due to a gastric perforation. Celecoxib with weekly docetaxel and estramustine is an effective and safe treatment for patients with
hormone-refractory prostate cancer, but it does not seem to add any benefit to docetaxel.
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Prostate cancer is the most common cancer among men in
developed countries. Every year, there are approximately 680000
new cases diagnosed and 220000 deaths around the world (Ferlay
et al, 2002). Despite improvements in early detection, about 10–20%
of men with prostate cancer present with metastatic disease, and
33% of men with early prostate cancer will develop metastases
despite local curative therapies, such as surgery or radiotherapy.
Based on past experience, the median time to metastases is about 8
years from the time of surgery in those men who have a prostate-
specific antigen (PSA) recurrence post-prostatectomy (Pound et al,
1999). Treatment of advanced or metastatic prostate cancer is
palliative. In about 80% of men, primary androgen ablation leads
to symptomatic improvement and a reduction in serum levels of
PSA, but eventually in most patients, the tumour becomes
androgen-independent after 18–24 months of castration
(Crawford et al, 1989). Later remissions with additional hormonal
therapies are less frequent and for shorter periods of time. Patients
with advanced hormone-refractory prostate cancer (HRPC) have a
progressive morbid disease with a median survival of 10–12
months.
Until recently, chemotherapy was considered to be ineffective in
HRPC (Yagoda and Petrylak, 1993). Mitoxantrone plus prednisone
(MP) palliates bone pain in 30% of patients but does not increase
survival (Tannock et al, 1996). Two recent randomised phase III
trials have shown a statistically significant survival benefit with
docetaxel in combination with estramustine (Petrylak et al, 2004)
or prednisone (Tannock et al, 2004) when compared to the
standard MP treatment. In a recent randomised phase II study,
weekly docetaxel in combination with estramustine and predni-
sone (EP) yielded similar efficacy results to those obtained by the
standard triweekly docetaxel plus EP, and both were significantly
superior to MP in terms of time to progression and PSA response
(Oudard et al, 2005). Unfortunately, the survival benefit found in
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sthe TAX327 later on was only detected with triweekly docetaxel,
but not with the weekly schedule. Apart from that, TAX327 trial
showed a different toxicity profile for weekly vs triweekly
docetaxel, specially regarding the incidence of severe neutropenia
that was more frequently observed in the triweekly rather than in
the weekly schedule (32 vs 2%, respectively) (Tannock et al, 2004).
Celecoxib belongs to a family of drugs called nonsteroidal anti-
inflammatory drugs (NSAIDs). It is a selective cyclooxygenase-2
(COX-2) inhibitor. Aberrant or increased expression of COX-2 has
been implicated in the pathogenesis of many diseases including
cancer. Cyclooxygenase-2 also has a key role in a wide variety of
processes related to carcinogenesis, including inhibition of
apoptosis, increased cell growth, increased cell migration, inhibi-
tion of the immune response and stimulation of angiogenesis
(Gumgumji et al, 2003).
Selective COX-2 inhibitors may play an important role in the
treatment of prostate cancer, because overexpression of COX-2 is
observed in the majority of human prostate carcinomas (Gupta
et al, 2000) and these agents have demonstrated the ability to
suppress tumour growth in prostate cancer cell lines (Liu et al,
2000). However, there are safety concerns to be taken into
consideration when selective COX-2 inhibitors are taken regularly
for long periods of time as they have been found to be associated
with an increased incidence of cardiovascular side effects.
To address these concerns, we carried out a prospective phase II
study to evaluate the efficacy and safety profile of weekly docetaxel
in combination with estramustine and celecoxib for the treatment
of patients with HRPC. The primary objective of the study was to
determine PSA response to study treatment. Secondary objectives
included the assessment of clinical response, time to progression,
overall survival and the safety profile.
MATERIALS AND METHODS
Study design
This was a multicenter, phase II, prospective, open label, non-
randomised trial in 12 hospitals in Spain. Recruitment of patients
took place from October 2003 to June 2005. The Institutional
Review Board of each participating site approved the study
protocol. All patients provided their written informed consent.
Clinical Research Forms were specifically designed to record the
study data and source data verification was performed on 100% of
study information.
Selection of patients
Eligibility criteria included histologically confirmed adenocarci-
noma of the prostate and progressive metastatic disease in spite of
androgen suppressive treatment. Progressive disease was defined
as the occurrence of at least one of the following conditions: (1)
increasing serum levels of PSA on two consecutive measurements
obtained at least 1 week apart (with a minimum level of PSA
410ngml
 1); (2) the appearance of new bone metastatic lesion(s)
and (3) 420% increase in the size of a previously existing lesion.
Patients had to be X18 years old, with a Karnofsky Index X60%
and a life expectancy of longer than 3 months together with
adequate bone marrow (neutrophils X1.5 10
9l
 1, platelets
4100 10
9l
 1 and haemoglobin X10gdl
 1) and renal and
hepatic function (serum creatinine o1.5 upper normal limit
(UNL); total bilirubin o1.25 UNL, aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT) o2.0 UNL).
Antiandrogen therapy had to be discontinued for at least 4–8
weeks depending on the type administered. Patients continued
taking luteinizing-hormone-releasing hormone agonists through-
out the study treatment period in order to maintain androgen
ablation. Prior radiotherapy and/or two previous hormonal
therapies were permitted if at least 4 weeks had elapsed since the
completion of those therapies.
Patients were excluded if they had been previously treated with
chemotherapy. Other exclusion criteria were the presence of
concomitant diseases including severe and uncontrolled cardio-
vascular disease, thromboembolic events in the last 6 months,
peripheral neuropathy of grade 2 or higher, history of another
cancer except those in complete remission for at least 2 years or
other serious medical condition. Patients were also ineligible if
they had hypersensitivity to celecoxib or allergy to estradiol,
sulphonamides or NSAIDs.
This study was conducted in accordance with the standards of
the Responsible Institutional Committees on Human Experimen-
tation and the Helsinki Declaration of the World Medical
Association amended in 1975 and subsequent revisions.
Therapy
Eligible patients were treated with 280mg of estramustine
(Estracyt
s, Pfizer Inc.) administered orally twice daily 1h before,
or 2h after, meals on days 1–3, 8–10 and 15–17 of the treatment
cycle. Celecoxib (Celebrex
s, Pfizer Inc.) was administered at a
dose of 400mg orally twice daily from day 1 until progression of
the disease or unacceptable toxicity. Docetaxel (Taxotere
s, Sanofi-
Aventis) 35mgm
 2 was administered as a 1-h intravenous
infusion weekly on days 2, 9 and 16 of the treatment cycle.
Treatment cycles were repeated every 28 days for at least 6 cycles.
Study treatment could be prolonged until progression of the
disease or unacceptable toxicity.
Prophylactic premedication included one dose of dexametha-
sone (8mg) administered orally 1h before each docetaxel infusion.
Antiemetic and gastric protector agents were administered
according to the usual practice at each hospital. No prophylactic
anticoagulant therapy was administered in this study.
Blood counts and serum biochemistry tests were conducted
before each cycle. If a patient showed a neutrophil count
o1.5 10
9l
 1 and/or a platelet count o100 10
9l
 1,c h e m o t h e r a p y
was delayed for 1 week. If toxicity persisted after 3 weeks, the
patient was withdrawn from the study. Docetaxel dosage was
reduced to 75% in the case of febrile neutropenia, prolonged
neutropenia (neutrophils o0.5 10
9l
 1 for longer than 5 days),
grade 3/4 thrombopenia along with haemorrhage or X2 weeks
delay in treatment due to toxicity. Patients were withdrawn from
the study after three or more reductions in docetaxel dosage. In
addition, study treatment was delayed for 1 week in the case of
grade 2 or higher non-haematological toxicity, excluding nausea
and vomiting, for a maximum of 2 weeks. Celecoxib was
interrupted in the case of bilirubin exceeding 3.0 UNL or
elevation of hepatic aminotransferases (ASAT and/or ALAT) to
42.5 UNL. Celecoxib therapy was restarted only when normal
values or grade 1 toxicity were achieved.
Evaluation of safety and response
Pre-study evaluations included complete medical history, the
recording of weight, height and Karnofsky performance status,
electrocardiogram, haematology and biochemistry tests including
measurement of serum PSA, and other examinations as clinically
indicated. Tumour measurements were performed by imaging-
based evaluations including computed tomography of the abdo-
men and pelvis, bone scanning and thorax radiography. Tumour
measurements were assessed at baseline and after two, four and six
treatment cycles.
Objective clinical response was evaluated according to the
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
(Therasse et al, 2000).
Serum PSA was measured after each treatment cycle and was
evaluated following recommendations from the Prostate-Specific
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sAntigen Working Group (Bubley et al, 1999). A PSA response was
defined when a confirmed decrease of at least 50% from baseline
was observed. Duration of the PSA response was defined as the
time between the first decrease of at least 50% of PSA from
baseline until an increase of 50% (to at least 5ngml
 1) over the
nadir.
Statistical analysis
The primary objective of the study was to determine PSA response
to study treatment. Secondary end points included analysis of
clinical response in measurable disease, time to progression,
overall survival and toxicity.
The sample size was calculated using the Simon method for
phase II trials. Taking into account a PSA response rate of 35%
achieved in previous studies with the standard schedule of MP, we
anticipated a response rate in PSA level of 55% with the new study
treatment. With a type I error of 5% and a study power of 80%, the
estimated sample size for this study was 44 evaluable patients.
Safety analyses were performed on patients who received at least
one treatment cycle (safety population). All toxicities recorded
were documented and graded according to the Common Toxicity
Criteria of the National Cancer Institute (Version 2).
Efficacy analyses were conducted on the intent-to-treat popula-
tion (efficacy population). Overall response rate (ORR) was
calculated with 95% confidence intervals (CIs). Time to progres-
sion was defined as the period of time from the start of the
treatment to first evidence of clinical or biochemical progression
or death. Survival was calculated from the date of first adminis-
tration of treatment to the date of death by any cause. Time to
progression and overall survival were analysed using the Kaplan–
Meier method.
RESULTS
Between October 2003 and June 2005, a total of 48 patients were
enrolled. The patient characteristics at baseline are shown in
Table 1. The median Karnofsky index was 80% and the median
time from first diagnosis was 37 months (range: 7–174 months).
Sixty percent of patients had stage IV disease at diagnosis. The
majority of patients (88%) had bone metastases and 31% of
patients had lymph nodes affected. Only 19 patients (40%) were
considered to have measurable disease. The median number of
disease lesions per patient was 3.5. Median PSA at baseline was 70
(range: 1–1193ngml
 1).
Treatment
A total of 207 cycles of estramustine, celecoxib and docetaxel were
administered, with a median number of four cycles per patient
(range: 1–9 cycles). Patients received 602 docetaxel infusions with
a median of 12 and a range of 3–27 infusions. However, 19
infusions of docetaxel (3% over 621 scheduled) needed to be
suspended due to non-treatment-related causes (8, 42%), non-
haematological toxicity (8, 42%), haematological toxicity (1, 5%),
and both haematological and non-hematological toxicities (2,
11%). Docetaxel dosage was reduced in 16 infusions (3% over 602
administered) of which nine were due to non-haematological
toxicity; six were due to non-drug-related causes and one due to
haematological toxicity.
The number of estramustine dosages was 600 out of 621
scheduled (97%). Only four dosages of estramustine needed to be
reduced due to non-haematological toxicity. The median absolute
and relative dose intensity for docetaxel and estramustine was
25.1mgm
 2week
 1 (96%) and 178.8mgday
 1 (99%), respectively.
Celecoxib was reduced in two patients, one due to patient decision
and the other one because of grade 3 epigastric toxicity.
Twenty-three patients (48%) completed treatment according to
protocol and 25 (52%) discontinued due to adverse events
(n¼13), patient decision (n¼5), investigator criteria (n¼3),
death (n¼3) and protocol violation (n¼1).
Efficacy
On an intention-to-treat analysis, PSA was decreased 450% in 28
out of 48 patients (ORR: 58%, 95% CI: 44–72). The median
duration of PSA response was 8.0 months (95% CI: 6.9–9.0). Of
19 patients with measurable disease, one CR and six PR were
observed (37%, CI 95%: 15–59), but only four of these were
subsequentially confirmed. Moreover, nine patients (47%) showed
SD and three patients (16%) progressed during the administration
of study treatment.
After a median follow-up of 11.3 months, the median time to
progression was 7.1 months (CI 95%: 5.3–8.8), and the median
overall survival was 19.2 months (CI 95%: 12.9–25.4) (Figure 1).
The median time to progression by PSA was 8.7 months (CI 95%:
7.7–9.8).
Safety
All patients were evaluated for toxicity (Table 2). The most
frequent grade 3/4 toxicity was asthenia (15% of patients, 4% of
cycles). Other severe non-haematological toxicities were diarrhoea
and stomatitis, each in of 8% of patients and 2% of cycles. Grade
3/4 anorexia, nausea and vomiting were reported in three patients
Table 1 Patient characteristics at baseline (n¼48)
Characteristic N %
Age (years)
Median 67
Range 48–78
Karnofsky index (%)
a
X80 37 77
o80 10 21
Prior treatments
Prostatectomy 16 33
Radiotherapy 26 54
Estramustine 3 6
Hormonal therapy 48 100
No. of previous hormonal treatments
11 9 4 0
21 6 3 3
421 3 2 7
Tumor stage
II 11 23
III 8 17
IV 29 60
Sites of disease
b
Bone 42 88
Soft tissue 15 31
Lymph node 3 6
Liver 3 6
Lung
No. of disease lesions
11 1 2 3
29 1 9
34 8
X42 4 5 0
aOne patient missed.
bPatients could be included in more than one category.
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s(6%), one cycle each. Regarding severe haematological toxicities,
anaemia was reported in three patients (6%) and six cycles (3%),
and neutropenia was reported in two patients (4%), one cycle each
(1%). The only severe cardiovascular events observed during the
study were two patients with oedema (4%), one patient with a deep
venous thromboembolism (2%) and one patient with a vasovagal
syncope (n¼1).
During the study, 13 patients (27%) were withdrawn from the
study due to adverse events and three patients died (6%). Toxicity-
related withdrawals were severe nail disorders (n¼3), dyspnoea
(n¼2), cutaneous toxicity (n¼2), asthenia (n¼1), haematologi-
cal toxicity (n¼1), oedema (n¼1), pain and poor general well-
being (n¼1), pulmonary embolism (n¼1) and femur fracture
(n¼1). Reasons for patient death during study treatment
administration were respiratory insufficiency (n¼1), encephalo-
pathy and renal failure (n¼1) and there was one toxic death
(n¼1). The only death that could be possibly related to treatment
was the toxic death. He was a 69-year-old man who, after the first
cycle of treatment, suffered grade 1/2 diarrhoea and vomiting
along with a severe antral gastric ulcer. The patient died 1 month
later from a gastric perforation possibly associated with the use of
celecoxib. The patient who died due to a respiratory insufficiency
suffered a deterioration of a previous concomitant disease; and the
encephalopathy and renal failure was supposed to be due to a
locoregional progression.
DISCUSSION
At this point in time, docetaxel is the only cytotoxic agent that has
shown a significant improvement in overall survival, palliation of
symptoms and improvement in quality of life for patients with
HRPC (Mike et al, 2006) when compared with the standard
combination of MP. The median overall survival achieved with
docetaxel-based chemotherapy, administered with estramustine or
prednisone, was close to 18 months (Petrylak et al, 2004; Tannock
et al, 2004) and PSA declined at least 50% in X45% of patients.
As far as we know, this study is the first reported phase II trial
that has addressed the question of whether the addition of a
selective COX-2 inhibitor such as celecoxib to this new standard
chemotherapy regimen gives further clinical benefit in HRPC
patients. Patients included in the study received an average of
25.1mgm
 2week
 1 of docetaxel and 178.8mgday
 1 of estramus-
tine over 4 months. Celecoxib was administered at 800mgday
 1
from the beginning of the study until disease progression or until
adverse events stopped the study. Efficacy results after this
schedule showed a PSA response in 58% of patients and a median
overall survival of 19.2 months, which are similar values to those
found in previous studies where docetaxel/estramustine or
docetaxel/prednisone was administered (Petrylak et al, 2004;
Tannock et al, 2004). Oudard et al (2005) observed a median
overall survival of 18.4 months and a PSA response rate of 63%
when docetaxel was administered in a similar dosage and schedule
(23.3mgm
 2week
 1) without celecoxib, but both estramustine
and prednisone were administered concomitantly with docetaxel.
It is known that the PSA response rate from prednisone alone is in
the range of 16–24% (Tannock et al, 1996; Berry et al, 2002), and
this fact could explain the results from that study and mask the
activity of celecoxib in this indirect comparison.
The clinical benefit observed in our study with the addition of
celecoxib to docetaxel/estramustine could have been even higher if
docetaxel had been administered every 3 weeks instead of every
week as recently reported (Tannock et al, 2004). However, only
preliminary data from a randomised phase II trial in which weekly
docetaxel plus EP yielded similar efficacy results to those obtained
by standard triweekly docetaxel plus EP were available at the time
of study design, and both were significantly superior than MP
(Oudard et al, 2005).
Our results are in agreement with recently published studies
where some evidence of the biological activity of celecoxib in
patients with prostate cancer was observed (Pruthi et al, 2006;
Smith et al, 2006). In a placebo-controlled study, celecoxib
significantly decreased mean PSA velocity (P¼0.02) and tended
to increase the proportion of men who doubled their PSA-doubling
time (Smith et al, 2006). In a second study, a slowing effect on the
rate of PSA after 3 months of treatment with celecoxib was
observed. This effect continued after 6, 12 and 18 months of
treatment, suggesting that celecoxib may have an effect on serum
PSA levels in patients with biochemical progression and therefore
could delay or prevent disease progression (Pruthi et al, 2006).
One of the reasons for administering docetaxel on a weekly basis
in our study instead of every 3 weeks was to avoid the high
incidence of grade 3/4 neutropenia and the moderate incidence of
thromboembolic events observed (Savarese et al, 2001). Certainly,
the toxicity profile of our study treatment was tolerable. Grade 3/4
neutropenia was observed in only two patients (4% of patients),
which compares well with the grade 3/4 neutropenia observed with
docetaxel in a triweekly treatment schedule in other studies, such
as CALGB 9780 (56% of patients) (Savarese et al, 2001), SWOG
9916 (16% of patients) (Petrylak et al, 2004) or TAX 327 trial (32%
Table 2 Grade 3/4 treatment-related toxicity (n¼48)
a
Toxicity Per patient (n¼48) N (%) Per cycle (n¼207) N (%)
Haematological
Anaemia 3 (6) 6 (3)
Neutropenia 2 (4) 2 (1)
Non-haematological
Asthenia 7 (15) 9 (4)
Diarrhoea 4 (8) 5 (2)
Stomatitis 4 (8) 4 (2)
Anorexia 3 (6) 3 (1)
Nausea 3 (6) 3 (1)
Vomiting 3 (6) 3 (1)
Dyspnea 2 (4) 3 (1)
Edema 2 (4) 2 (1)
Onycholisis 2 (4) 2 (1)
aReported in two or more patients (X4% of patients).
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Figure 1 Overall survival (n¼48).
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sof patients) (Tannock et al, 2004). But it was very similar to that
observed in the docetaxel weekly arm of TAX 327 trial (2% of
patients). The incidence of other severe haematological and non-
haematological toxicities was low. The most frequent grade 3/4
adverse events was asthenia (15% of patients), which is known
to be one of the dose-limiting toxicities of weekly docetaxel
(Hainsworth et al, 1998; Sitka Copur et al, 2001).
It has been reported that COX-2 inhibitors can minimise certain
typical side effects of chemotherapy such as mucositis, diarrhoea
and other inflammatory toxic effects. Cyclooxygenase-2 inhibitors
may also be useful to control chronic pain that is very frequent in
patients with advanced prostate cancer (Gasparini et al, 2003).
However, during treatment administration, there was one toxic
death. This was a 69-year-old man who, after the first cycle of
treatment, suffered a severe antral gastric ulcer and gastric
perforation that may have been associated with the use of
celecoxib. It has been reported that celecoxib can delay healing
in patients with complicated gastric ulcers, but at this point,
only one previous case of gastric perforation has been reported to
be associated with the use of celecoxib (Reuben and Steinberg,
1999).
In conclusion, this study shows that celecoxib in combination
with weekly docetaxel plus estramustine is an effective and feasible
treatment for patients with HRPC. The results obtained in this
clinical trial may indicate that celecoxib could further improve the
efficacy results obtained by docetaxel-based chemotherapy regi-
mens in this type of patients. However, more studies like the
STAMPEDE trial are needed to confirm these initial findings. The
STAMPEDE trial is designed to assess the safety and efficacy of
docetaxel, celecoxib and zoledronic acid given in various
combinations. We will see if a clinical benefit is obtained with
these drugs, and also if this benefit outweighs the potential risks
associated with the long-term administration of selective COX-2
inhibitors.
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